Regeneron-Sanofi’s drug for lung disease gets US approval
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs
Health
Pharma
Drugs
Health
Pharma
US drug regulator blocks Regeneron’s blood cancer therapy
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.